Delayed payouts, family disputes, and red tape await those who skip this critical step. Here’s why updating your EPF and EPS ...

Analysts highlight MariTide's upcoming updates and near-term catalysts, while Amgen's price targets shift amid steady outlook ...

Q1 2025 Earnings Call Transcript May 1, 2025 Ascendis Pharma A/S misses on earnings expectations. Reported EPS is $-1.79348 EPS, expectations were $-1.56. Operator: Ladies and gentlemen, thank you for ...

Loss per share of $0.14, adjusted loss per share of $0.02, better than outlook Net debt down $35 million year over year, with ...

Q1 2025 Earnings Call Transcript April 30, 2025 Glaukos Corporation beats earnings expectations. Reported EPS is $-0.22, ...

Operator: Good day, and welcome to the Spire Inc. Q2 FY 2025 Earnings Conference Call. All participants will be in ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Good morning, ladies and gentlemen, and welcome to the Teleflex First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded, and we ...

On a GAAP basis, revenue for Qorvo’s fiscal 2025 fourth quarter was $869.5 million, gross margin was 42.2%, operating income was $28.2 million, and diluted earnings per share was $0.33. On a non-GAAP ...

Qorvo® (Nasdaq:QRVO), a leading global provider of connectivity and power solutions, today announced financial results for the Company's fiscal 2025 ...